CD24 and breast carcinoma: For example, Gupta and colleagues [73] utilized a chemical screen to identify drugs with selective toxicity for BCSCs and found that salinomycin was able to reduce the prevalence of CD44+/CD24− BCSCs compared to paclitaxel, a commonly used breast cancer chemotherapeutic agent.